Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir, an orally active RdRp inhibitor, is in a phas...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/26/19/5795 |
| _version_ | 1797515970045018112 |
|---|---|
| author | Mohd. Imran Mandeep Kumar Arora Syed Mohammed Basheeruddin Asdaq Shah Alam Khan Saleh I. Alaqel Mohammed Kanan Alshammari Mohammed M. Alshehri Ahmed Subeh Alshrari Alreshidi Mateq Ali Ahmed Muteb Al-shammeri Bushra Dhuhayyan Alhazmi Aishah Ali Harshan Md. Tauquir Alam Abida |
| author_facet | Mohd. Imran Mandeep Kumar Arora Syed Mohammed Basheeruddin Asdaq Shah Alam Khan Saleh I. Alaqel Mohammed Kanan Alshammari Mohammed M. Alshehri Ahmed Subeh Alshrari Alreshidi Mateq Ali Ahmed Muteb Al-shammeri Bushra Dhuhayyan Alhazmi Aishah Ali Harshan Md. Tauquir Alam Abida |
| author_sort | Mohd. Imran |
| collection | DOAJ |
| description | The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir, an orally active RdRp inhibitor, is in a phase 3 clinical trial against COVID-19. The objective of this review article is to enlighten the researchers working on COVID-19 about the discovery, recent developments, and patents related to molnupiravir. Molnupiravir was originally developed for the treatment of influenza at Emory University, USA. However, this drug has also demonstrated activity against a variety of viruses, including SARS-CoV-2. Now it is being jointly developed by Emory University, Ridgeback Biotherapeutics, and Merck to treat COVID-19. The published clinical data indicate a good safety profile, tolerability, and oral bioavailability of molnupiravir in humans. The patient-compliant oral dosage form of molnupiravir may hit the market in the first or second quarter of 2022. The patent data of molnupiravir revealed its granted compound patent and process-related patent applications. We also anticipate patent filing related to oral dosage forms, inhalers, and a combination of molnupiravir with marketed drugs like remdesivir, favipiravir, and baricitinib. The current pandemic demands a patient compliant, safe, tolerable, and orally effective COVID-19 treatment. The authors believe that molnupiravir meets these requirements and is a breakthrough COVID-19 treatment. |
| first_indexed | 2024-03-10T06:54:43Z |
| format | Article |
| id | doaj.art-214ea3796c5a4269be217ab2bb78ed1b |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-10T06:54:43Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-214ea3796c5a4269be217ab2bb78ed1b2023-11-22T16:32:45ZengMDPI AGMolecules1420-30492021-09-012619579510.3390/molecules26195795Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19Mohd. Imran0Mandeep Kumar Arora1Syed Mohammed Basheeruddin Asdaq2Shah Alam Khan3Saleh I. Alaqel4Mohammed Kanan Alshammari5Mohammed M. Alshehri6Ahmed Subeh Alshrari7Alreshidi Mateq Ali8Ahmed Muteb Al-shammeri9Bushra Dhuhayyan Alhazmi10Aishah Ali Harshan11Md. Tauquir Alam12Abida13Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi ArabiaSchool of Pharmaceutical and Population Health Informatics, DIT University, Dehradun 248009, Uttarakhand, IndiaDepartment of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi ArabiaCollege of Pharmacy, National University of Science and Technology, Muscat 130, OmanDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi ArabiaDepartment of Pharmaceutical Care, Rafha Central Hospital, North Zone, Rafha 91911, Saudi ArabiaPharmaceutical Care Department, Ministry of National Guard-Health Affairs, Riyadh 11426, Saudi ArabiaMedical Laboratory Technology Department, Faculty of Applied Medical Science, Northern Border University, Arar 91431, Saudi ArabiaDepartment of Medical Laboratory Sciences, Sulaiman ALrajhi University, Albukairah 51941, Saudi ArabiaPharmaceutical Affairs, Dammam Health Network, Eastern Health Cluster, Dammam 31146, Saudi ArabiaFaculty of Pharmacy, Northern Border University, Rafha 91911, Saudi ArabiaDepartment of Pharmaceutical Care, Northern Area Armed Forces Hospital, King Khalid Military City Hospital, Hafr Al-Batin 31991, Saudi ArabiaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi ArabiaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi ArabiaThe COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir, an orally active RdRp inhibitor, is in a phase 3 clinical trial against COVID-19. The objective of this review article is to enlighten the researchers working on COVID-19 about the discovery, recent developments, and patents related to molnupiravir. Molnupiravir was originally developed for the treatment of influenza at Emory University, USA. However, this drug has also demonstrated activity against a variety of viruses, including SARS-CoV-2. Now it is being jointly developed by Emory University, Ridgeback Biotherapeutics, and Merck to treat COVID-19. The published clinical data indicate a good safety profile, tolerability, and oral bioavailability of molnupiravir in humans. The patient-compliant oral dosage form of molnupiravir may hit the market in the first or second quarter of 2022. The patent data of molnupiravir revealed its granted compound patent and process-related patent applications. We also anticipate patent filing related to oral dosage forms, inhalers, and a combination of molnupiravir with marketed drugs like remdesivir, favipiravir, and baricitinib. The current pandemic demands a patient compliant, safe, tolerable, and orally effective COVID-19 treatment. The authors believe that molnupiravir meets these requirements and is a breakthrough COVID-19 treatment.https://www.mdpi.com/1420-3049/26/19/5795molnupiravirEIDD-2801MK-4482EIDD-1931patentsSARS-CoV-2 |
| spellingShingle | Mohd. Imran Mandeep Kumar Arora Syed Mohammed Basheeruddin Asdaq Shah Alam Khan Saleh I. Alaqel Mohammed Kanan Alshammari Mohammed M. Alshehri Ahmed Subeh Alshrari Alreshidi Mateq Ali Ahmed Muteb Al-shammeri Bushra Dhuhayyan Alhazmi Aishah Ali Harshan Md. Tauquir Alam Abida Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19 Molecules molnupiravir EIDD-2801 MK-4482 EIDD-1931 patents SARS-CoV-2 |
| title | Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19 |
| title_full | Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19 |
| title_fullStr | Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19 |
| title_full_unstemmed | Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19 |
| title_short | Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19 |
| title_sort | discovery development and patent trends on molnupiravir a prospective oral treatment for covid 19 |
| topic | molnupiravir EIDD-2801 MK-4482 EIDD-1931 patents SARS-CoV-2 |
| url | https://www.mdpi.com/1420-3049/26/19/5795 |
| work_keys_str_mv | AT mohdimran discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 AT mandeepkumararora discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 AT syedmohammedbasheeruddinasdaq discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 AT shahalamkhan discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 AT salehialaqel discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 AT mohammedkananalshammari discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 AT mohammedmalshehri discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 AT ahmedsubehalshrari discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 AT alreshidimateqali discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 AT ahmedmutebalshammeri discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 AT bushradhuhayyanalhazmi discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 AT aishahaliharshan discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 AT mdtauquiralam discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 AT abida discoverydevelopmentandpatenttrendsonmolnupiraviraprospectiveoraltreatmentforcovid19 |